John Hrom

416 total citations
15 papers, 78 citations indexed

About

John Hrom is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, John Hrom has authored 15 papers receiving a total of 78 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in John Hrom's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers) and CAR-T cell therapy research (2 papers). John Hrom is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers) and CAR-T cell therapy research (2 papers). John Hrom collaborates with scholars based in United States, Israel and United Kingdom. John Hrom's co-authors include Sergio Huerta, Debabrata Saha, Thomas Anthony, Xiaohuan Gao, Payal Kapur, Nizar M. Tannir, Shahrooz Eshaghian, Robert A. Figlin, James R. Berenson and Nancy A. Dawson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Experimental Hematology.

In The Last Decade

John Hrom

13 papers receiving 78 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Hrom United States 6 47 26 25 20 17 15 78
Ryan P. Frazier United States 4 41 0.9× 15 0.6× 25 1.0× 16 0.8× 10 0.6× 5 84
C-J. Yen Taiwan 4 68 1.4× 49 1.9× 12 0.5× 13 0.7× 7 0.4× 7 102
Alexander Andreev-Drakhlin United States 4 32 0.7× 20 0.8× 15 0.6× 11 0.6× 7 0.4× 10 68
Georgia Makrypidi‐Fraune Germany 6 52 1.1× 50 1.9× 19 0.8× 21 1.1× 5 0.3× 7 125
J.J. Soto Castillo Spain 4 38 0.8× 50 1.9× 6 0.2× 11 0.6× 7 0.4× 14 103
Donne Bennett Caces United States 7 60 1.3× 21 0.8× 9 0.4× 59 3.0× 29 1.7× 9 114
Montse Muñoz Spain 6 49 1.0× 21 0.8× 11 0.4× 15 0.8× 5 0.3× 6 91
Richard Riedel Germany 6 50 1.1× 32 1.2× 16 0.6× 15 0.8× 18 1.1× 28 128
Gloria Margiotta Casaluci Italy 5 60 1.3× 10 0.4× 7 0.3× 72 3.6× 34 2.0× 11 99
C. Lerchenmueller Germany 4 63 1.3× 8 0.3× 8 0.3× 17 0.8× 12 0.7× 7 79

Countries citing papers authored by John Hrom

Since Specialization
Citations

This map shows the geographic impact of John Hrom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Hrom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Hrom more than expected).

Fields of papers citing papers by John Hrom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Hrom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Hrom. The network helps show where John Hrom may publish in the future.

Co-authorship network of co-authors of John Hrom

This figure shows the co-authorship network connecting the top 25 collaborators of John Hrom. A scholar is included among the top collaborators of John Hrom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Hrom. John Hrom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Goldman, Jonathan W., Shun Lü, Jair Bar, et al.. (2025). LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein–overexpressing non-squamous EGFR -wildtype advanced NSCLC: Efficacy outcomes by prior therapy.. Journal of Clinical Oncology. 43(16_suppl). 8618–8618. 1 indexed citations
3.
4.
Opat, Stephen, John Hrom, David Kliman, et al.. (2024). BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia.. Journal of Clinical Oncology. 42(16_suppl). TPS7090–TPS7090. 3 indexed citations
5.
Opat, Stephen, John Hrom, David Kliman, et al.. (2024). BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia. Blood. 144(Supplement 1). 1661.1–1661.1. 1 indexed citations
6.
Trněný, Marek, Abraham Avigdor, Matthew McKinney, et al.. (2023). Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study. EClinicalMedicine. 63. 102130–102130. 3 indexed citations
7.
8.
Lynch, Ryan C., Abraham Avigdor, Matthew McKinney, et al.. (2021). Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203). Blood. 138(Supplement 1). 813–813. 7 indexed citations
9.
Lynch, Ryan C., Shankara Paneesha, Abraham Avigdor, et al.. (2020). Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203). Blood. 136(Supplement 1). 36–37. 7 indexed citations
10.
Tannir, Nizar M., Neeraj Agarwal, Nancy A. Dawson, et al.. (2019). CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 37(7_suppl). TPS682–TPS682. 9 indexed citations
11.
Berenson, James R., Tanya M. Spektor, Jacob D. Bitran, et al.. (2017). Replacement of ixazomib for relapsed/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy.. Journal of Clinical Oncology. 35(15_suppl). 8013–8013. 11 indexed citations
12.
Schwartzberg, Lee S., Nashat Gabrail, John Hrom, et al.. (2016). Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender.. Journal of Clinical Oncology. 34(15_suppl). e21700–e21700. 1 indexed citations
13.
Huerta, Sergio & John Hrom. (2011). Oxaliplatin as a radiosensitizing agent in rectal cancer. Anti-Cancer Drugs. 22(4). 317–323. 5 indexed citations
14.
Huerta, Sergio, John Hrom, Xiaohuan Gao, et al.. (2010). Tissue microarray constructs to predict a response to chemoradiation in rectal cancer. Digestive and Liver Disease. 42(10). 679–684. 27 indexed citations
15.
Hrom, John, et al.. (2007). A rare case of signet ring cell gastric adenocarcinoma.. PubMed. 48(9). 271–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryan P. Frazier Breakdown of academic impact, for papers by C-J. Yen Breakdown of academic impact, for papers by Alexander Andreev-Drakhlin Breakdown of academic impact, for papers by Georgia Makrypidi‐Fraune Breakdown of academic impact, for papers by J.J. Soto Castillo Breakdown of academic impact, for papers by Donne Bennett Caces Breakdown of academic impact, for papers by Montse Muñoz Breakdown of academic impact, for papers by Richard Riedel Breakdown of academic impact, for papers by Gloria Margiotta Casaluci Breakdown of academic impact, for papers by C. Lerchenmueller
Rankless by CCL
2026